To say that mortality has always been something to avoid is an understatement. In the evolutionary history of life delaying mortality must have been a powerful selectable trait. Delaying mortality is something not all species are equally good at. For example, while bowhead whales can live for over 200 years, our most favorite experimental animal, the mouse, cannot expect to live longer than about 3 years, and that is under optimal conditions in our animal facilities. In the wild they usually die around 8 months, from cold, lack of food or predation. Humans soon found out that even in the best of times mortality was a given. Especially the rich and powerful had a problem with that, which explains that so many kings and emperors tried their utmost to gain immortality. Since then humans never stopped trying to find ways to ward off death from old age and even now there are plenty of aggressively advertised interventions to save us from aging. Alas, the far majority of such interventions are far from the realm of regular medicine and can better be avoided.But very recently something changed in anti-aging medicine and this time it came not from charlatans but from serious scientists. This is not obvious because regular science for quite a long time expressed no interest in research on aging, which was considered the exclusive domain of charlatans. What happened and led serious scientists change their mind was the discovery that aging, like a disease, could be targeted for intervention. Not for gaining immortality but for increasing the health span of life. This is the topic of the book Age Later, Health Span, Life Span, and the New Science of Longevity by Nir Barzilai. Nir is a friend and colleague of mine and I know him for a long time. His new book describes the promise of the new science of aging in a lighthearted, entertaining style, but with all the facts in good order and narrated so clearly that also the non-scientist will be able to follow the main concepts presented.The book is focused on the recently emerged new field of āGeroscienceā, the study of aging at the interface of its basic biological principles and the diseases it will cause late in life. Why is this an important book? The main problem investigators who study aging have always experienced is the lack of practical appeal of the science of aging and therefore very limited funding. This is primarily based on vested interest. The established behemoths of medical research, cancer, cardiovascular disease, diabetes, have incentives to block a switch to a different universe where individual diseases are no longer the be-all and end-all of medicine. That is, until Geroscience came along. As described in the book, the main impact of Geroscience is to once and for all put the lie to the idea that aging is inevitable and cannot be targeted for medical intervention. This book, for example, does that very effectively in Chapter 7, Making Eighty the New Sixty, providing a lucid description of where we can go from here based on the stream of new, convincing scientific data that interventions in aging are possible and will have a major impact on prevention and treatment of chronic disease. It should open the eyes of politicians, investors and the medical establishment to a new world that is coming.One way to turn Geroscience into the disruptive technology that it could be is to make people understand that things do not need to be the way they are. That is, it should not be necessary to become increasingly fearful when approaching 60 and then 70 that one of the big diseases will catch you. Age Later is a manifesto to underscore a new future. A future where everybody will have access to medication that targets multiple chronic diseases simultaneously rather than one by one by targeting the basic mechanisms of aging that underlie all these diseases. This also makes economic sense. As described in Chapter 1, One Hundred Years Young, those who live to a hundred because they have the right genes suffer less and have many more years of healthy old age than the average human. However, also the health care costs of such a lucky individual are only a fraction of the health care costs of that average individual. As described further on in the book, the genomes of these slow agers have now become treasure troves for investigators interested in finding out how they do it. What are the genetic variants that dictate a healthy long live? If we would know that, we could use such genes as starting points to develop drugs that mimic these good genes so that also the far majority of humanity, which normally would have to do without, can still profit from them.Age Later does the job of providing all that critical information in a way that is clear to the non-scientist, convincing for investors and persuasive for politicians to make the necessary changes in the medical establishment. In this respect the story of the TAME trial in Chapter six, The Quest to Prove Aging can be Targeted, is critically important because it shows that it actually is possible to get at least some of the regulators on your side.The book is well organized with a number of informative boxes to quickly outline specific scientific aspects important in following the reasoning. It ends, quite appropriately, with the future, in a Chapter called Bright Horizons that discusses some of the hottest areas of potential interventions. Overall a book to point the way as to how Geroscience is on its way to disrupt the medical sciences and change our future.